Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent"), a technology-based company with a well-established laboratory services ...

Fulgent is set to buy Bako Diagnostics assets and StrataDx for $55.5M, expanding into anatomic pathology and dermatopathology to scale lab services.

Out of the 386 regencies and mayoralties targeted by the Health Ministry, fewer than half are estimated to have public health ...

The addition of Bako and StrataDx is anticipated to bolster Fulgent’s lab services business with the inclusion of new ...

Earlier this year the Therapeutic Goods Administration (TGA) halted the sale of 21 sunscreen products in Australia following ...

On 17 December 2025, the World Health Organization (WHO) announced the prequalification of two rapid antigen diagnostic tests ...

Diego Cardeñosa always knew he wanted to study sharks. But when he started his Ph.D., he had to make a choice: tagging sharks ...

In this interview, Dr. Gary Pestano and Dr. Prithwish Pal discuss the advantages ddPCR offers in molecular residual disease ...

Detailed price information for Fulgent Genetics Inc (FLGT-Q) from The Globe and Mail including charting and trades.

Delafloxacin may be more effective than current treatments at inhibiting intracellular replication of bacteria genus ...

In this interview, Dr. Denise Heaney discusses how molecular diagnostics are reshaping antimicrobial stewardship and ...

Blood-based Biomarker for Alzheimer’s Disease Market to reach US$ 554.2 Mn by 2035 at 14.3% CAGR, driven by demand for ...